文献リスト

1) Levy RH, Mattson RH, Meldrum BS, et al, editors. Antiepileptic Drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002

2) Wyllie E, editor. The Treatment of Epilepsy: Principles and Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006

3) Levy RH, Bourgeois BFD, Hachad H. Drug-drug interactions. In: Engel J, Pedley TA, editors. Epilepsy. A Comprehensive Textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, A Wolters Kluwer Business. 2008. p. 1235-48

4) Marson AG, Kadir ZA, Hutton JL, et al. Gabapentin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2000; (3): CD001415

5) Jette NJ, Marson AG, Hutton JL, et al. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2002; (3): CD001417

6) Ramaratnam S, Marson AG, Baker GA. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2001; (3): CD001909

7) Chaisewikul R, Privitera MD, Hutton JL, et al. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane Database Syst Rev. 2001; (1): CD001901

8) Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia. 1999; 40: 1147-54

9) Wheless JW, Neto W, Wang S. Topiramate, carbamazepine, and valproate monotherapy: double blind comparison in children with newly diagnosed epilepsy. J Child Neurol. 2004; 19: 135-41

10) Glauser TA, Dlugos DJ, Dodson WE, et al. EPMN-106/INT-28 Investigators. Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. J Child Neurol. 2007; 22: 693-9

11) Duchowny M, Pellock JM, Graf WD, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology. 1999; 53: 1724-31

12) Nieto-Barrera M, Brozmanova M, Capovilla G, et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res. 2001; 46: 145-55

13) Glauser TA, Ayala R, Elterman RD, et al. N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006; 66: 1654-60

14) Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev. 2003; (3)CD003032

15) Trudeau V, Myers S, LaMoreaux L, et al. Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol. 1996; 11: 470-5

16) Biton V, Sackellares JC, Voung A, et al. Double-blind, placebo-controlled study of lamotorigine in primary generalized tonic-clonic seizures. Neurology. 2005; 65: 1737-43

17) Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology. 1999; 52: 1330-7

18) Berkovic SF, Knowlton RC, Leroy RF, et al. Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology. 2007; 69: 1751-60

19) Noachtar S, Andermann E, Meyvisch P, et al. N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 2008; 70: 607-16

20) Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med. 1997; 337: 1807-12

21) Sachdeo RC, Glauser AT, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. 1999; 52: 1882-7

22) de los Reyes EC, Sharp GB, Williams JP, et al. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol. 2004; 30: 254-6

23) Lagae L, Deconinck A, Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol. 2003; 7: 123-8

24) Marson AG, AL-Kharusi, Alwaidth M, et al. The SANAD study of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007; 369: 1000-15

25) Marson AG, AL-Kharusi, Alwaidth M, et al. The SANAD study of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007; 369: 1016-26

26) Castillo S, Schmidt DB, White S. Oxcarbazepine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2000; (3): CD002028

27) Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology. 2000; 54: 2237-44

28) Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997; 27: 205-13

29) Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008; 70: 1950-8

30) Kassai B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: a systemic review and a meta-analysis of individual patient data. Epilepsia. 2008; 49: 343-8

31) Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrom. Epilepsia. 2009; 50: 2362-8

32) Meador KJ, Baker GA, Browing N, et al. NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009; 360: 1597-605

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp